<DOC>
	<DOCNO>NCT00946153</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , efficacy , safety tolerability , pharmacokinetics , pharmacodynamics , anti-tumor effect E7080 administer continually daily patient advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Study E7080 Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically clinically confirm diagnosis advance HCC 2 . Eastern Cooperative Oncology GroupPerformance Status ( ECOGPS ) : 01 3 . Adequate laboratory values/organ function test Exclusion criterion : 1 . Simultaneous metachronous cancer 2 . Pericardial , ascites , pleural effusion require drainage 3 . Brain metastasis/meningeal carcinomatosis present clinical symptom require treatment 4 . Malabsorption syndrome 5 . Arteryportal vein shunt arteryvein shunt prevent proper diagnosis tumor 6 . Use drug know inhibit cytochrome P3A4</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Hepatocellular</keyword>
</DOC>